Biegel & Waller LLC Holds Stake in Bristol-Myers Squibb Company (BMY)
Biegel & Waller LLC held its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,920 shares of the biopharmaceutical company’s stock at the close of the second quarter. Biegel & Waller LLC’s holdings in Bristol-Myers Squibb were worth $330,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. State Street Corp grew its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the period. Jennison Associates LLC grew its stake in shares of Bristol-Myers Squibb by 5.4% during the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after purchasing an additional 1,184,652 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the period. Legal & General Group Plc grew its stake in shares of Bristol-Myers Squibb by 2.7% during the 2nd quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after purchasing an additional 217,920 shares during the period. Finally, Swiss National Bank grew its stake in shares of Bristol-Myers Squibb by 27.2% during the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares during the period. Institutional investors own 69.51% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.99 on Tuesday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The stock has a market capitalization of $99,609.57, a price-to-earnings ratio of 20.56, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the business earned $0.77 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by company insiders.
A number of equities research analysts have recently commented on BMY shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price on the stock. in a research report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and set a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a research report on Thursday, August 24th. UBS AG reiterated a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup Inc. increased their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $64.93.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.